Document_and_Entity_Informatio
Document and Entity Information | 9 Months Ended | |
Sep. 30, 2013 | Nov. 05, 2013 | |
Document And Entity Information [Abstract] | ' | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 30-Sep-13 | ' |
Document Fiscal Year Focus | '2013 | ' |
Document Fiscal Period Focus | 'Q3 | ' |
Trading Symbol | 'NANX | ' |
Entity Registrant Name | 'NANOPHASE TECHNOLOGIES CORPORATION | ' |
Entity Central Index Key | '0000883107 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Common Stock, Shares Outstanding | ' | 28,468,162 |
BALANCE_SHEETS
BALANCE SHEETS (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
Current assets: | ' | ' |
Cash and cash equivalents | $3,307,104 | $4,124,234 |
Investments | 30,000 | 30,000 |
Trade accounts receivable, less allowance for doubtful accounts of $6,000 on September 30, 2013 and December 31, 2012 | 988,304 | 1,031,405 |
Other receivables | 844 | 27,167 |
Inventories, net | 990,756 | 1,138,482 |
Prepaid expenses and other current assets | 226,894 | 240,870 |
Total current assets | 5,543,902 | 6,592,158 |
Equipment and leasehold improvements, net | 2,629,851 | 3,027,671 |
Other assets, net | 27,971 | 29,829 |
Total assets | 8,201,724 | 9,649,658 |
Current liabilities: | ' | ' |
Current portion of capital lease obligations | 30,052 | 34,526 |
Accounts payable | 583,424 | 680,452 |
Accrued expenses | 553,685 | 484,460 |
Total current liabilities | 1,167,161 | 1,199,438 |
Long-term portion of capital lease obligations | 18,397 | 62,755 |
Long-term deferred rent | 633,646 | 636,628 |
Asset retirement obligations | 158,424 | 153,967 |
Total long-term liabilities | 810,467 | 853,350 |
Contingent liabilities | ' | ' |
Stockholders' equity: | ' | ' |
Preferred stock, $.01 par value, 24,088 shares authorized and no shares issued and outstanding | ' | ' |
Common stock, $.01 par value, 35,000,000 shares authorized; 28,468,162 and 28,458,162 shares issued and outstanding on September 30, 2013 and December 31, 2012, respectively | 284,682 | 284,582 |
Additional paid-in capital | 95,707,861 | 95,512,065 |
Accumulated deficit | -89,768,447 | -88,199,777 |
Total stockholders' equity | 6,224,096 | 7,596,870 |
Total liabilities and stockholders' equity | $8,201,724 | $9,649,658 |
BALANCE_SHEETS_Parenthetical
BALANCE SHEETS (Parenthetical) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
Statement Of Financial Position [Abstract] | ' | ' |
Trade accounts receivable, less allowance for doubtful accounts | $6,000 | $6,000 |
Preferred stock, par value | $0.01 | $0.01 |
Preferred stock, shares authorized | 24,088 | 24,088 |
Preferred stock, shares issued | ' | ' |
Preferred stock, shares outstanding | ' | ' |
Common stock, par value | $0.01 | $0.01 |
Common stock, shares authorized | 35,000,000 | 35,000,000 |
Common stock, shares issued | 28,468,162 | 28,458,162 |
Common stock, shares outstanding | 28,468,162 | 28,458,162 |
STATEMENTS_OF_OPERATIONS_Unaud
STATEMENTS OF OPERATIONS (Unaudited) (USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Revenue: | ' | ' | ' | ' |
Product revenue, net | $2,156,844 | $2,028,529 | $7,810,058 | $7,061,504 |
Other revenue | 7,106 | 72,435 | 16,356 | 231,591 |
Net revenue | 2,163,950 | 2,100,964 | 7,826,414 | 7,293,095 |
Operating expense: | ' | ' | ' | ' |
Cost of revenue | 1,648,417 | 1,571,575 | 5,555,601 | 5,349,594 |
Gross profit | 515,533 | 529,389 | 2,270,813 | 1,943,501 |
Research and development expense | 375,442 | 396,503 | 1,257,263 | 1,210,168 |
Selling, general and administrative expense | 772,644 | 789,169 | 2,590,596 | 2,546,334 |
Loss from operations | -632,553 | -656,283 | -1,577,046 | -1,813,001 |
Interest income | 379 | ' | 1,123 | ' |
Interest expense | -1,623 | -2,056 | -10,748 | -5,093 |
Other, net | 901 | ' | 18,001 | 7,199 |
Loss before provision for income taxes | -632,896 | -658,339 | -1,568,670 | -1,810,895 |
Provision for income taxes | ' | ' | ' | ' |
Net loss | ($632,896) | ($658,339) | ($1,568,670) | ($1,810,895) |
Net loss per share - basic and diluted | ($0.02) | ($0.02) | ($0.06) | ($0.08) |
Weighted average number of basic and diluted common shares outstanding | 28,468,162 | 26,960,880 | 28,467,686 | 23,139,731 |
STATEMENTS_OF_CASH_FLOWS_Unaud
STATEMENTS OF CASH FLOWS (Unaudited) (USD $) | 9 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Operating activities: | ' | ' |
Net loss | ($1,568,670) | ($1,810,895) |
Adjustment to reconcile net loss to net cash used in operating activities: | ' | ' |
Depreciation and amortization | 674,082 | 749,666 |
Stock compensation expense | 191,872 | 222,673 |
Gain on disposal of equipment | -18,001 | ' |
Allowance for excess inventory quantities | 47,017 | ' |
Changes in assets and liabilities related to operations: | ' | ' |
Trade accounts receivable | 43,101 | 8,940 |
Other receivables | 26,323 | 13,712 |
Inventories | 100,709 | 46,221 |
Prepaid expenses and other current assets | 13,976 | 123,120 |
Accounts payable | -168,920 | 289,032 |
Accrued expenses | 67,268 | 87,742 |
Deferred other revenue | ' | 67,998 |
Net cash used in operating activities | -591,243 | -201,791 |
Investing activities: | ' | ' |
Proceeds from disposal of equipment | 18,001 | ' |
Acquisition of equipment and leasehold improvements | -177,652 | -116,969 |
Payment of accounts payable incurred for the purchase of equipment and leasehold improvements | -20,404 | -14,941 |
Net cash used in investing activities | -180,055 | -131,910 |
Financing activities: | ' | ' |
Principal payments on capital leases | -48,832 | -14,796 |
Proceeds from stockholder rights offering, net of costs | ' | 2,220,432 |
Proceeds from exercise of stock options | 3,000 | ' |
Net cash (used in) / provided by financing activities | -45,832 | 2,205,636 |
(Decrease) / increase in cash and cash equivalents | -817,130 | 1,871,935 |
Cash and cash equivalents at beginning of period | 4,124,234 | 2,693,623 |
Cash and cash equivalents at end of period | 3,307,104 | 4,565,558 |
Supplemental cash flow information: | ' | ' |
Interest paid | 10,748 | 5,093 |
Supplemental non-cash investing activities: | ' | ' |
Accounts payable incurred for the purchase of equipment and leasehold improvements | 92,296 | 11,677 |
Capital lease obligations incurred in the purchase of equipment | ' | $120,359 |
Basis_of_Presentation
Basis of Presentation | 9 Months Ended |
Sep. 30, 2013 | |
Accounting Policies [Abstract] | ' |
Basis of Presentation | ' |
(1) Basis of Presentation | |
The accompanying unaudited interim financial statements of Nanophase Technologies Corporation (“Nanophase” or the “Company”, including “we”, “our” or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair presentation of the financial position and operating results of the Company for the interim periods presented. Operating results for the three and nine month periods ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. | |
These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2012, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission. |
Description_of_Business
Description of Business | 9 Months Ended |
Sep. 30, 2013 | |
Accounting Policies [Abstract] | ' |
Description of Business | ' |
(2) Description of Business | |
Nanophase is a nanomaterials and applications developer and commercial manufacturer with an integrated family of nanomaterial and related technologies. Nanophase produces engineered nano and sub-micron materials for use in a variety of diverse existing and developing markets: personal care including sunscreens, architectural coatings, architectural window cleaning and restoration, industrial coating ingredients, abrasion-resistant additives, plastics additives, medical diagnostics, energy and a variety of polishing applications, including semiconductors and optics. We target markets in which we believe practical solutions may be found using our products. We work closely with current and potential customers in these target markets to identify their material and performance requirements and market our materials to various end-use applications manufacturers. Recently developed technologies have made certain new products possible and opened potential new markets. Although our primary strategic focus has been the North American market, we currently sell material to customers overseas and have been working to expand our reach in foreign markets. | |
The Company was incorporated in Illinois in November 1989, and became a Delaware corporation in November 1997. The Company’s common stock trades on the OTCQB marketplace under the symbol NANX. | |
While product sales comprise the majority of our revenue, we also recognized revenue in connection with a technology license (through 2012) and other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason we classify such revenue as “other revenue” in our Statement of Operations, as it does not represent revenue directly from our nanocrystalline materials. |
Financial_Instruments
Financial Instruments | 9 Months Ended |
Sep. 30, 2013 | |
Fair Value Disclosures [Abstract] | ' |
Financial Instruments | ' |
(3) Financial Instruments | |
We follow the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. | |
Our financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair values of all financial instruments were not materially different from their carrying values. |
Investments
Investments | 9 Months Ended |
Sep. 30, 2013 | |
Investments Debt And Equity Securities [Abstract] | ' |
Investments | ' |
(4) Investments | |
Investments on September 30, 2013 and December 31, 2012 were comprised of certificates of deposit in the amount of $30,000, pledged as collateral for the Company’s rent and restricted as to withdrawal or usage. |
Inventories
Inventories | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Inventories | ' | ||||||||
(5) Inventories | |||||||||
Inventories consist of the following: | |||||||||
September 30, | December 31, | ||||||||
2013 | 2012 | ||||||||
Raw materials | $ | 184,492 | $ | 199,257 | |||||
Finished goods | 853,281 | 999,391 | |||||||
1,037,773 | 1,198,648 | ||||||||
Allowance for excess inventory quantities | (47,017 | ) | (60,166 | ) | |||||
$ | 990,756 | $ | 1,138,482 | ||||||
ShareBased_Compensation
Share-Based Compensation | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||||||
Share-Based Compensation | ' | ||||||||
(6) Share-Based Compensation | |||||||||
We follow FASB ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. We recognized compensation expense related to stock options of $54,141 and $192,896 for the three and nine month periods ended September 30, 2013, compared to $62,203 and $225,104 for the same periods in 2012. | |||||||||
As of September 30, 2013, there was approximately $289,000 of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Company’s stock option plans. That cost is expected to be recognized over a remaining weighted-average period of 1.7 years. | |||||||||
Stock Options and Stock Grants | |||||||||
During the nine months ended September 30, 2013, proceeds of $3,000 were realized, and 10,000 shares of common stock were issued pursuant to option exercises compared to none for the same period in 2012. During the nine months ended September 30, 2013, 553,000 stock options were granted compared to 547,000 stock options granted during the same period in 2012. During the nine months ended September 30, 2013, 112,799 stock options were forfeited, compared to 168,732 stock options forfeited during the same period in 2012. | |||||||||
Stock Appreciation Rights | |||||||||
Prior to 2011, we granted outside directors stock appreciation rights (SARs). The change in fair value of the awards granted during prior years is included in non-cash compensation expense for the three and nine months ended September 30, 2013 and 2012. The SARs granted vested immediately and are payable upon the directors’ removal or resignation from the position of director. These awards are accounted for as liability awards, included in accrued expenses as of September 30, 2013 and 2012, and adjusted to fair value each reporting period. The fair value of the liability on September 30, 2013 was $7,725 compared to $8,749 on December 31, 2012. | |||||||||
As of September 30, 2013, we did not have any unvested restricted stock or performance shares outstanding. | |||||||||
The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for stock options granted during the periods presented: | |||||||||
For the nine months ended | September 30, | September 30, | |||||||
2013 | 2012 | ||||||||
Weighted-average risk-free interest rates: | 1.5 | % | 1.1 | % | |||||
Dividend yield: | — | — | |||||||
Weighted-average expected life of the option: | 7 Years | 7 Years | |||||||
Weighted-average expected stock price volatility: | 92 | % | 85 | % | |||||
Weighted-average fair value of the options granted: | $ | 0.33 | $ | 0.23 |
Significant_Customers_and_Cont
Significant Customers and Contingencies | 9 Months Ended |
Sep. 30, 2013 | |
Text Block [Abstract] | ' |
Significant Customers and Contingencies | ' |
(7) Significant Customers and Contingencies | |
Sales to three customers constituted approximately 74%, 5% and 8%, respectively, of our total revenue for the three months ended September 30, 2013, and 71%, 7% and 5%, respectively, of our total revenue for the nine months ended September 30, 2013. Amounts included in accounts receivable on September 30, 2013 relating to these three customers were approximately $624,000, $111,000 and $178,000, respectively. Revenue from these three customers constituted approximately 62%, 5% and 7%, respectively, of our total revenue for the three months ended September 30, 2012, as compared to 68%, 5% and 4%, respectively, of our total revenue for the nine months ended September 30, 2012. Amounts included in accounts receivable on September 30, 2012 relating to these three customers were approximately $602,000, $97,000 and $88,000, respectively. | |
We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements, certain other obligations and/or certain financial covenants. The most restrictive financial covenants in one of our supply agreements with BASF “trigger” a technology transfer right (license and equipment sale at BASF’s option) in the event (a) that earnings of the twelve month period ending with our most recently published quarterly financial statements are less than zero and our cash, cash equivalents and certain investments are less than $1,000,000, or (b) of an acceleration of any debt maturity having a principal amount of more than $10,000,000. Our supply agreements with BASF also “trigger” a technology transfer right in the event of our insolvency, as further defined within the agreements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment's net book value, or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value. | |
We believe that we have sufficient cash (See Liquidity and Capital Resources in Management’s Discussion and Analysis in Part I, Item 2 of this Form 10-Q for a further discussion) to operate our business during 2013. If a triggering event were to occur and BASF elected to proceed with the license and related equipment sale mentioned above, we would receive royalty payments from this customer for products sold using our technology; however, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success and could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us. Finally, any shortfall in capital needed to operate the business as management intends, including with respect to avoiding this triggering event as described above, may result in a curtailment of certain activities or anticipated investments. |
Business_Segmentation_and_Geog
Business Segmentation and Geographical Distribution | 9 Months Ended |
Sep. 30, 2013 | |
Segment Reporting [Abstract] | ' |
Business Segmentation and Geographical Distribution | ' |
(8) Business Segmentation and Geographical Distribution | |
Revenue from international sources approximated $278,000 and $735,000 for the three and nine months ended September 30, 2013 compared to $187,000 and $466,000 for the same periods in 2012. Other revenue recognized from a Japanese licensee was $0 for the three and nine months ended September 30, 2013, compared to $68,000 and $211,000 for the same periods of 2012. The agreement expired during March of 2013. | |
Our operations comprise a single business segment and all of our long-lived assets are located within the United States. |
Financial_Instruments_Policies
Financial Instruments (Policies) | 9 Months Ended |
Sep. 30, 2013 | |
Fair Value Disclosures [Abstract] | ' |
Fair Value Measurements and Disclosures | ' |
We follow the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. | |
Share-Based Payments | ' |
We follow FASB ASC Topic 718, Share-Based Payments, in which compensation expense is recognized only for share-based payments expected to vest. We recognized compensation expense related to stock options of $54,141 and $192,896 for the three and nine month periods ended September 30, 2013, compared to $62,203 and $225,104 for the same periods in 2012. |
Inventories_Tables
Inventories (Tables) | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Inventory Disclosure [Abstract] | ' | ||||||||
Summary of Inventories | ' | ||||||||
Inventories consist of the following: | |||||||||
September 30, | December 31, | ||||||||
2013 | 2012 | ||||||||
Raw materials | $ | 184,492 | $ | 199,257 | |||||
Finished goods | 853,281 | 999,391 | |||||||
1,037,773 | 1,198,648 | ||||||||
Allowance for excess inventory quantities | (47,017 | ) | (60,166 | ) | |||||
$ | 990,756 | $ | 1,138,482 | ||||||
ShareBased_Compensation_Tables
Share-Based Compensation (Tables) | 9 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ||||||||
Schedule of Assumptions Used to Calculate the Black-Scholes Option Pricing Model for Stock Options Granted | ' | ||||||||
The following table illustrates the various assumptions used to calculate the Black-Scholes option pricing model for stock options granted during the periods presented: | |||||||||
For the nine months ended | September 30, | September 30, | |||||||
2013 | 2012 | ||||||||
Weighted-average risk-free interest rates: | 1.5 | % | 1.1 | % | |||||
Dividend yield: | — | — | |||||||
Weighted-average expected life of the option: | 7 Years | 7 Years | |||||||
Weighted-average expected stock price volatility: | 92 | % | 85 | % | |||||
Weighted-average fair value of the options granted: | $ | 0.33 | $ | 0.23 |
Investments_Additional_Informa
Investments - Additional Information (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
Investments All Other Investments [Abstract] | ' | ' |
Certificates of deposit | $30,000 | $30,000 |
Inventories_Summary_of_Invento
Inventories - Summary of Inventories (Detail) (USD $) | Sep. 30, 2013 | Dec. 31, 2012 |
Inventory Disclosure [Abstract] | ' | ' |
Raw materials | $184,492 | $199,257 |
Finished goods | 853,281 | 999,391 |
Inventory gross, Total | 1,037,773 | 1,198,648 |
Allowance for excess inventory quantities | -47,017 | -60,166 |
Inventories net, Total | $990,756 | $1,138,482 |
ShareBased_Compensation_Additi
Share-Based Compensation - Additional Information (Detail) (USD $) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Share-based compensation expense | $54,141 | $62,203 | $192,896 | $225,104 | ' |
Total unrecognized compensation cost related to nonvested share-based compensation arrangements granted | 289,000 | ' | 289,000 | ' | ' |
Weighted-average period over which unrecognized compensation is expected to be recognized | ' | ' | '1 year 8 months 12 days | ' | ' |
Proceeds from exercise of stock options | ' | ' | 3,000 | ' | ' |
Common stock issued pursuant to option exercises | ' | ' | 10,000 | ' | ' |
Stock options granted | ' | ' | 553,000 | 547,000 | ' |
Stock options forfeited | ' | ' | 112,799 | 168,732 | ' |
Shares outstanding | 28,468,162 | ' | 28,468,162 | ' | 28,458,162 |
Stock Appreciation Rights (SARs) [Member] | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Fair value of the liability | $7,725 | ' | $7,725 | ' | 8,749 |
Restricted Stock [Member] | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Shares outstanding | 0 | ' | 0 | ' | ' |
Performance Shares [Member] | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' |
Shares outstanding | 0 | ' | 0 | ' | ' |
ShareBased_Compensation_Schedu
Share-Based Compensation - Schedule of Assumptions Used to Calculate the Black-Scholes Option Pricing Model for Stock Options Granted (Detail) (USD $) | 9 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ' | ' |
Weighted-average risk-free interest rates: | 1.50% | 1.10% |
Dividend yield: | ' | ' |
Weighted-average expected life of the option: | '7 years | '7 years |
Weighted-average expected stock price volatility: | 92.00% | 85.00% |
Weighted-average fair value of the options granted: | $0.33 | $0.23 |
Significant_Customers_and_Cont1
Significant Customers and Contingencies - Additional Information (Detail) (USD $) | 3 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | |||||||
Sep. 30, 2013 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Customer | Customers One [Member] | Customers One [Member] | Customers One [Member] | Customers One [Member] | Customers Two [Member] | Customers Two [Member] | Customers Two [Member] | Customers Two [Member] | Customers Three [Member] | Customers Three [Member] | Customers Three [Member] | Customers Three [Member] | ||
Revenue, Major Customer [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of sales | ' | ' | 74.00% | 62.00% | 71.00% | 68.00% | 5.00% | 5.00% | 7.00% | 5.00% | 8.00% | 7.00% | 5.00% | 4.00% |
Accounts receivable | $988,304 | $1,031,405 | $624,000 | $602,000 | $624,000 | $602,000 | $111,000 | $97,000 | $111,000 | $97,000 | $178,000 | $88,000 | $178,000 | $88,000 |
Number of major customers | 3 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Recovered_Sheet1
Significant Customers And Contingencies - Additional Information -BASF Supply Agreement (Detail) (USD $) | 9 Months Ended |
Sep. 30, 2013 | |
Unusual Risk or Uncertainty [Line Items] | ' |
Events which could potentially result in the license of technology and/or the sale of production equipment | 'Contractual covenants that have contingencies outlined which could potentially result in the license of technology and/or the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customerbs production needs. This outcome may occur if we fail to meet certain performance requirements, certain other obligations and/or certain financial condition covenants. The financial condition covenants in one of our supply agreements with BASF btriggerb a technology transfer right (license and equipment sale at BASFbs option) in the event (a) that earnings of the twelve month period ending with our most recently published quarterly financial statements are less than zero and our cash, cash equivalents and certain investments are less than $1,000,000, or (b) of an acceleration of any debt maturity having a principal amount of more than $10,000,000. |
Options for the sale of property plant and equipment | 'In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipmentbs net book value, or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipmentbs net book value. |
Scenario, Option One [Member] | ' |
Unusual Risk or Uncertainty [Line Items] | ' |
Minimum contractual covenant - net earnings previous twelve months | 0 |
Minimum contractual covenant - cash and cash equivalents | 1,000,000 |
Scenario, Option Two [Member] | ' |
Unusual Risk or Uncertainty [Line Items] | ' |
Maximum contractual covenant - principal amount of debt with an accelerated maturity date | 10,000,000 |
Option One [Member] | ' |
Unusual Risk or Uncertainty [Line Items] | ' |
Property plant and equipment sale percent of carrying value | 30.00% |
Option Two [Member] | ' |
Unusual Risk or Uncertainty [Line Items] | ' |
Property plant and equipment sale percent of net book value | 115.00% |
Business_Segmentation_and_Geog1
Business Segmentation and Geographical Distribution - Additional Information (Detail) (Non-Domestic Revenue [Member], USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Revenue from External Customer [Line Items] | ' | ' | ' | ' |
Revenue from international sources | $278,000 | $187,000 | $735,000 | $466,000 |
Product Revenue [Member] | ' | ' | ' | ' |
Revenue from External Customer [Line Items] | ' | ' | ' | ' |
Revenue from international sources | 278,000 | 187,000 | 735,000 | 466,000 |
Japanese License [Member] | ' | ' | ' | ' |
Revenue from External Customer [Line Items] | ' | ' | ' | ' |
Revenue from international sources | $0 | $68,000 | $0 | $211,000 |
Royalty Arrangement [Member] | ' | ' | ' | ' |
Revenue from External Customer [Line Items] | ' | ' | ' | ' |
Agreement expiration date | ' | ' | 31-Mar-13 | ' |